drugset
drugset / Trial / NCT04984525

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525 ↗

Phase 1 Completed 106 enrolled Synlogic
RandomizedCrossoverTriple-blindTreatment

Summary

This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV). Eligible subjects receive investigational product (IP) and undergo safety monitoring, evaluations, and subsequent follow-up after IP administration.

Timeline

Start
2021-07-02
Primary completion
2021-12-10
Completion
2021-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject LABAFENOGENE MARSELECOBAC Cell therapy 3e+11 cells Oral
Subject LABAFENOGENE MARSELECOBAC Cell therapy 6e+11 cells Oral
Subject LABAFENOGENE MARSELECOBAC Cell therapy 1e+12 cells Oral
Subject SYNB1618 Other / unclassified 6e+11 cells Oral

Indications

No indication recorded.